Minimal residual disease-directed individualized therapy for hematological malignancies / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
;
(12): 12-17, 2023.
Artigo
em Chinês
| WPRIM
| ID: wpr-988946
ABSTRACT
Minimal residual disease (MRD) has been used for warning of relapse and guiding the therapy selection for hematological malignancies including acute leukemia. Based on MRD-related content reported at the 64th American Society of Hematology (ASH) Annual Meeting, this article discusses the progress of MRD-directed individualized therapy for hematological malignancies with a primary focus on acute myeloid leukemia.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Journal of Leukemia & Lymphoma
Ano de publicação:
2023
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS